Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +15 locations
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Register for Updates
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06630247
Recruiting
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Exelixis Clinical Site #4, Denver, Colorado +9 locations
Conditions: Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Register for Updates
FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support
NCT06915090
Recruiting
In individuals with overweight/obesity, increases in physical activity (PA) can improve metabolic and cardiovascular health, independent of weight loss. However, PA levels are often low in individuals with overweight/obesity, and primary care providers (PCPs) are tasked with addressing this issue. The investigative team developed and successfully piloted integrating a Fitbit program into clinical care, where patients were referred by PCPs, and PCPs could view PA data in the Epic electronic healt... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/03/2025
Locations: UMass Chan Medical School, Worcester, Massachusetts
Conditions: GLP - 1, Diabetes, Obesity and Obesity-related Medical Conditions, Cardiovascular Diseases
Register for Updates
Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR
NCT04383808
Recruiting
The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: Stanford University, Palo Alto, California
Conditions: Brain Disease
Register for Updates
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04958265
Recruiting
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Gender:
ALL
Ages:
Between 28 days and 17 years
Trial Updated:
04/03/2025
Locations: University of California Davis Medical Center, Sacramento, California +42 locations
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
NCT05393258
Recruiting
This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small doses on a specific timed interval, instead of delivering one large dose at one time. This technique may improve efficacy while reducing toxicity and improving patient quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant
Register for Updates
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
NCT05673928
Recruiting
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Solid Tumor, Brain Metastases
Register for Updates
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
NCT05918692
Recruiting
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic, Phoenix, Arizona +22 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
NCT06094478
Recruiting
Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The "Door-In-Door-Out" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US "stand up" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut +4 locations
Conditions: Stroke, Acute, Ischemic Stroke, Acute, Hemorrhagic Stroke
Register for Updates
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NCT06295770
Recruiting
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Fibrillary Glomerulonephritis
Register for Updates
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
NCT06500884
Recruiting
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Yale University School Of Medicine, New Haven, Connecticut +7 locations
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332
Recruiting
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/03/2025
Locations: University of Utah, Salt Lake City, Utah +3 locations
Conditions: Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Register for Updates